Ray Shao retweeted
Nice to see RCT of RT for gallbladder ca.
Results not surprising that adjuvant chemoRT did not have better DFS/OS v chemo, given most gallbladder tumors recur distantly plus ~95% had R0 resection.
Findings mostly support current practices of offering chemoRT only for +margins.
📢Adjuvant GemCis vs CRT with capecitabine in gallbladder cancer
GECCOR-GB study
@JAMAOnc
➡️Phase II
➡️Resected stage II/III, R0 or R1
✅1-year DFS: %88.9 vs 77.8%
✅2-year DFS: 74.8% vs 74.8%
✅Completion of planned trratment: 82% vs 62%
✅Both met primary endpoint of 1-y DFS 77%
👉doi:10.1001/jamaoncol.2024.1944
@JAMA_current @curecc @CCA_Alliance @CholangioNet @PrecisionBTCnet
#cancer #oncology #biliary #MedX
Ray Shao retweeted
What imaging do you use to follow anal cancer patients s/p chemoRT?
We do: PET at 10-12 weeks & if still uptake, another ~3 mo later. Once normalized, CT CAP q6-12 mo.
But this isn't consistent w NCCN guidelines – which recommends no f/u PET, no short-term imaging at all.
RT @NiuSanford: Nice paper. I find treatment of lymph nodes challenging in rectal cancer.
In OCUM study, MRI accuracy for predicting LN in…
This quoted post is unavailable.
Ray Shao retweeted
Appreciate the critique & counterpoint to our editorial here. Although it seems the authors agreed w @BobTimmermanMD & me on most points (but then said we were wrong 😀).
Thanks to @IJROBP for facilitating the dialogue.
redjournal.org/article/S0360…
Ray Shao retweeted
Incredible RCT w 118 patients receiving sham RT.
‼️ Impressive RCT showing reduction of ranibizumab treatment burden & cost using SBRT to treat neovascular age-related macular degeneration.
Stereotactic radiotherapy for neovascular age-related macular degeneration (STAR) - The Lancet thelancet.com/journals/lance…
@xrtGenomics @seanmmcbride @JingLi_MD_PhD @Dan_ChangMD
Ray Shao retweeted
In this week's @JAMA_current, my husband @EthanLSanford writes about the deaths of our daughter Ceci and his patient Terry.
About how grief has informed his practicing of medicine and living a fuller life.
Please read about our girl and share.
jamanetwork.com/journals/jam…
Ray Shao retweeted
Curious others thoughts on this take @SuyogCancer @DocCatenacci
Ray Shao retweeted
ESOPEC: some initial thoughts.
As predicted, FLOT beat out CROSS – not surprising given pitching best systemic agents x 4 mo against weaker radiosensitizing chemotherapy over 5 weeks, in a disease site with high rate distant recurrence. 1/6
#ASCO24